Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT06553352
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanubrutinib combined with Obinutuzumab — DRUG
    Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.

Study Details

To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.

Key Dates

First listed
Aug 14, 2024
Start date
Mar 31, 2024
Status verified
Aug 2024
Primary completion
Apr 20, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zanubrutinib (Z) combined with Obinutuzumab (O)
    Zanubrutinib (Z) 160mg bid oral d1-21 Obinutuzumab (O) C1 1000mg d1,8,15 C2-C6 d1 IV, then every 8 weeks until full 20 infusions (1 years maintenance)

Primary Outcome Measure

CR [ Time Frame: up to 1 year ]

Central Contacts

Related Studies